Sexual dysfunction in Parkinson's disease

被引:114
作者
Bronner, G
Royter, V
Korczyn, AD
Giladi, N
机构
[1] Tel Aviv Souraski Med Ctr, Dept Neurol, Movement Disorders Unit, IL-64239 Tel Aviv, Israel
[2] Tel Aviv Univ, Sackler Sch Med, Sieratzki Chair Neurol, IL-69978 Tel Aviv, Israel
关键词
D O I
10.1080/00926230490258893
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Sexual dysfunction is common in Parkinson's disease (PD). We investigated the premorbid and present sexual functioning of 75 people with PD (32 women and 43 men). Women reported difficulties with arousal (87.5%), with reaching orgasm (75.0%), with low sexual desire (46.9%), and wih sexual dissatisfaction (37.5%). Men reported erectile dysfunction (68.4%), sexual dissatisfaction (65.1%), premature ejaculation (40.6%), and difficulties reaching orgasm (39.5%). Premorbid sexual dysfunction may contribute to cessation of sexual activity during the course of the disease (among 23.3% men and 21.9% women). Associated illnesses, use of medications, and advanced stage of PD contributed to sexual dysfunction.
引用
收藏
页码:95 / 105
页数:11
相关论文
共 46 条
[1]   Neurophysiology/pharmacology of erection [J].
Andersson, KE .
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2001, 13 :S8-S17
[2]  
Basson R, 2001, ADV NEUROL, V86, P295
[3]  
Basson R, 1996, Parkinsonism Relat Disord, V2, P177, DOI 10.1016/S1353-8020(96)00020-X
[4]  
BRODERICK GA, 1994, SEXUAL DYSFUNCTION N, P299
[5]  
Bronner G, 2001, Harefuah, V140, P72
[6]  
Bronner Gila, 2003, P517
[7]  
BROWN E, 1978, AM J PSYCHIAT, V135, P1552
[8]   SEXUAL FUNCTION IN PATIENTS WITH PARKINSONS-DISEASE AND THEIR PARTNERS [J].
BROWN, RG ;
JAHANSHAHI, M ;
QUINN, N ;
MARSDEN, CD .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1990, 53 (06) :480-486
[9]   BROMOCRIPTINE INDUCED IMPOTENCE IN PARKINSONS-DISEASE [J].
CLEEVES, L ;
FINDLEY, LJ .
BRITISH MEDICAL JOURNAL, 1987, 295 (6594) :367-368
[10]   Psychiatric and sexual disorders induced by apomorphine in Parkinson's disease [J].
Courty, E ;
Durif, F ;
Zenut, M ;
Courty, P ;
Lavarenne, J .
CLINICAL NEUROPHARMACOLOGY, 1997, 20 (02) :140-147